Biosimulation - Market Size, Share, Industry Trends, and Growth Forecasts, 2026-2031 | AI, Cloud, and Regulatory Adoption Propel Market to USD 11.3 Billion
Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Biosimulation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
The global biosimulation market is estimated at USD 5.22 billion in 2026, up from USD 4.47 billion in 2025. The market is projected to reach USD 11.3 billion by 2031, expanding at a compound annual growth rate of 16.72% during 2026-2031. Growth is being driven by rising healthcare-sector IT budgets, increasing regulatory acceptance of model-informed drug development, cloud-based computing adoption, and demand for more efficient drug discovery and clinical development processes.
Healthcare-Sector Technology Investment Accelerates Market Growth
Life-sciences organizations continue to increase technology spending, with artificial-intelligence initiatives becoming a leading investment priority. Larger IT budgets are supporting the deployment of integrated biosimulation platforms that combine physiologically based pharmacokinetic modeling, quantitative systems pharmacology, and AI capabilities.
Pharmaceutical companies are also investing in cloud-native modeling environments to reduce development costs, improve collaboration, and conduct complex virtual studies. These platforms allow research teams in multiple locations to work with shared models and data in real time. Cloud-based high-performance computing further lowers simulation costs by giving companies access to flexible computing capacity without requiring extensive infrastructure investment.
Regulatory Support Strengthens Biosimulation Adoption
Growing acceptance from global regulatory agencies is encouraging pharmaceutical and biotechnology companies to incorporate biosimulation into development programs. The US Food and Drug Administration reports continued growth in QSP-based submissions, while its permanent model-informed drug development paired-meeting program provides structured regulatory guidance.
The ICH M15 guideline, finalized in 2024, has also established more consistent international expectations for model-informed drug development. In addition, the European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency have published detailed guidance covering PBPK modeling. Regulators are increasingly considering simulation evidence as an alternative to selected animal studies, including research involving monoclonal antibodies. This expanding regulatory acceptance reduces uncertainty for sponsors and strengthens the role of biosimulation in clinical and preclinical decision-making.
Skills and Awareness Gaps Remain Key Challenges
Despite favorable market conditions, limited familiarity among clinicians and trial teams continues to restrict adoption. Some investigators lack the training needed to interpret quantitative modeling outputs and apply virtual evidence to protocol design. Pharmaceutical companies are responding through internal training academies and e-learning programs, but adoption remains uneven across therapeutic areas and geographic markets.
The shortage of experienced PBPK and QSP modelers presents an additional challenge. This skills gap is particularly significant in emerging markets, where digital infrastructure is less developed and local regulators are only beginning to incorporate international modeling guidelines. Expanding specialized education and practical training will be essential to unlocking the full value of biosimulation platforms.
Software Leads as Services Record Strong Growth
Software accounted for 67.10% of biosimulation market revenue in 2025, reflecting strong demand for integrated modeling environments that support visualization, model verification, compound screening, and regulatory reporting. Vendors are adding AI modules, intuitive dashboards, and extensive compound libraries to PBPK and QSP platforms, enabling research teams to evaluate candidates more efficiently.
Services are projected to grow at an 18.05% CAGR through 2031. Demand is increasing as sponsors seek specialized support to customize workflows, interpret complex outputs, and integrate real-time biosensor data into digital twin models. This trend is extending biosimulation beyond traditional drug development into chronic-disease management and clinical decision support. Providers combining software platforms with consulting and data-engineering expertise are well positioned to support complex late-stage projects.
Subscription Delivery Models Gain Momentum
Ownership-based deployments represented 46.90% of revenue in 2025 because many large pharmaceutical companies continue to operate advanced internal data centers. However, subscription models are forecast to expand at an 18.70% CAGR as organizations prioritize flexible computing capacity, lower capital expenditure, continuous software updates, and embedded compliance capabilities.
Security and data-sovereignty requirements continue to support on-premise and hybrid deployments, particularly for proprietary biologic sequences and sensitive clinical trial data. Hybrid environments allow companies to retain confidential workloads behind internal firewalls while using cloud resources for additional computing capacity. Containerized platforms that operate consistently across cloud and on-premise environments are expected to support further adoption.
North America Leads While Asia-Pacific Expands Fastest
North America held a 44.10% share of global biosimulation market revenue in 2025. Its leadership is supported by favorable FDA policies, substantial venture funding, advanced research infrastructure, and early adoption of quantitative modeling for complex biologics. Europe remains a major market due to extensive EMA guidance, strong data-privacy standards, secure cloud investment, and collaboration among software developers, pharmaceutical companies, and research hospitals.
Asia-Pacific is forecast to register the fastest regional CAGR of 22.60%. Regulatory harmonization, a growing biosimilar pipeline, and expanding pharmaceutical innovation in China, Japan, and India are supporting this growth. Lower operating costs and a growing population of data scientists are also helping regional companies establish dedicated biosimulation capabilities.
Latin America, the Middle East, and Africa currently account for smaller market shares but are attracting greater interest as multinational sponsors extend virtual-study methods to more diverse populations. Technology-transfer programs, wider cloud availability, and improving access to real-world data are expected to create additional long-term opportunities across these emerging biosimulation markets.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Healthcare-Sector IT Budgets
4.2.2 Growing Adoption of Biosimulation Platforms by Regulators
4.2.3 Escalating Drug-Development Costs
4.2.4 Cloud-Based High-Performance Computing Cuts Simulation TCO
4.2.5 FDA MIDD Program Mainstreams Model-Based Submissions
4.2.6 Expansion of Real-World-Data-Driven 'Virtual-Twin' Studies
4.3 Market Restraints
4.3.1 Limited Awareness Among Clinicians & Trial Teams
4.3.2 Shortage of Skilled PBPK/QSP Modelers
4.3.3 Lack of Global Data-Format & Model-Validation Standards
4.3.4 Regulatory Uncertainty Around AI-Generated Models
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitutes
4.4.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value in USD)
5.1 By Product
5.1.1 Software
5.1.2 Services
5.2 By Delivery Model
5.2.1 Subscription
5.2.2 Ownership / On-premise
5.3 By Application
5.3.1 Pre-clinical & Clinical Drug Development
5.3.2 Drug Discovery & Lead Optimization
5.3.3 Precision-medicine & Companion-diagnostics Design
5.4 By End User
5.4.1 Pharmaceutical & Biotechnology Companies
5.4.2 Contract Research Organizations
5.4.3 Academic & Research Institutes
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Certara
6.3.2 Dassault Systemes (BIOVIA)
6.3.3 Simulations Plus
6.3.4 Schrodinger
6.3.5 Genedata
6.3.6 Leadscope
6.3.7 Entelos
6.3.8 In Silico Biosciences
6.3.9 Pharmaceutical Product Development
6.3.10 Compugen
6.3.11 Applied BioMath
6.3.12 GNS Healthcare
6.3.13 VeriSIM Life
6.3.14 Insilico Medicine
6.3.15 Syntekabio
6.3.16 Simcyp
6.3.17 Garuda Therapeutics
6.3.18 Ansys (subsidiary MEDINI)
6.3.19 Cadence Design Systems
6.3.20 EMD Serono
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/6rq53j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.